CytRx Corporation  

(Public, NASDAQ:CYTR)   Watch this stock  
Find more results for CYTR
2.60
+0.02 (0.78%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.53 - 2.71
52 week 2.08 - 8.35
Open 2.58
Vol / Avg. 387,102.00/697,035.00
Mkt cap 144.92M
P/E     -
Div/yield     -
EPS -0.98
Shares 55.74M
Beta 1.72
Inst. own 46%
Nov 4, 2014
Q3 2014 CytRx Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -15828.48%
Operating margin - -9198.15%
EBITD margin - -9158.01%
Return on average assets -22.30% -116.20%
Return on average equity -27.98% -232.62%
Employees 17 -
CDP Score - -

Address

Suite 650, 11726 San Vicente Blvd
LOS ANGELES, CA 90049
United States - Map
+1-310-8265648 (Phone)
+1-310-8266139 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.

Officers and directors

Marvin R. Selter Independent Vice Chairman of the Board
Age: 86
Bio & Compensation  - Reuters
John Y. Caloz Chief Financial Officer
Age: 62
Bio & Compensation  - Reuters
Daniel Levitt M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Benjamin S. Levin Senior Vice President, General Counsel, Corporate Secretary
Age: 37
Bio & Compensation  - Reuters
Douglas Scott Wieland Ph.D. Senior Vice President - Drug Development
Age: 54
Bio & Compensation  - Reuters
Shanta Chawla M.D. Vice President - Clinical Development
Bio & Compensation  - Reuters
David J. Haen Vice President - Business Development
Age: 35
Bio & Compensation  - Reuters
Steven A Kriegsman Chairman of the Board, President, Chief Executive Officer
Age: 72
Bio & Compensation  - Reuters
Louis J. Ignarro Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Joseph Rubinfeld Ph.D. Independent Director
Age: 81
Bio & Compensation  - Reuters